Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Safety and Efficacy of Retreating with Immunotherapy After Immune-Related Adverse Events in Patients with NSCLC.

Santini FC, Rizvi H, Plodkowski AJ, Ni A, Lacouture ME, Gambarin-Gelwan M, Wilkins O, Panora E, Halpenny DF, Long NM, Kris MG, Rudin CM, Chaft JE, Hellmann MD.

Cancer Immunol Res. 2018 Jul 10. pii: canimm.0755.2017. doi: 10.1158/2326-6066.CIR-17-0755. [Epub ahead of print]

PMID:
29991499
2.

Pathologic Features of Response to Neoadjuvant Anti-PD-1 in Resected Non-Small Cell Lung Carcinoma: A Proposal for Quantitative Immune-Related Pathologic Response Criteria (irPRC).

Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, Rekhtman N, Anders RA, Cuda JD, Illei PB, Gabrielson E, Askin FB, Niknafs N, Smith KN, Velez MJ, Sauter JL, Isbell JM, Jones DR, Battafarano RJ, Yang SC, Danilova L, Wolchok JD, Topalian SL, Velculescu VE, Pardoll DM, Brahmer JR, Hellmann MD, Chaft JE, Cimino-Mathews A, Taube JM.

Ann Oncol. 2018 Jul 6. doi: 10.1093/annonc/mdy218. [Epub ahead of print]

PMID:
29982279
3.

YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.

Fan PD, Narzisi G, Jayaprakash AD, Venturini E, Robine N, Smibert P, Germer S, Yu HA, Jordan EJ, Paik PK, Janjigian YY, Chaft JE, Wang L, Jungbluth AA, Middha S, Spraggon L, Qiao H, Lovly CM, Kris MG, Riely GJ, Politi K, Varmus H, Ladanyi M.

Proc Natl Acad Sci U S A. 2018 Jun 26;115(26):E6030-E6038. doi: 10.1073/pnas.1717782115. Epub 2018 Jun 6.

4.

FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients with Non-Small-Cell Lung Cancer.

Spigel DR, Chaft JE, Gettinger S, Chao BH, Dirix L, Schmid P, Chow LQM, Hicks RJ, Leon L, Fredrickson J, Kowanetz M, Sandler A, Funke R, Rizvi NA.

J Thorac Oncol. 2018 May 15. pii: S1556-0864(18)30603-8. doi: 10.1016/j.jtho.2018.05.004. [Epub ahead of print]

PMID:
29775807
5.

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, Battafarano RJ, Velez MJ, Rekhtman N, Olah Z, Naidoo J, Marrone KA, Verde F, Guo H, Zhang J, Caushi JX, Chan HY, Sidhom JW, Scharpf RB, White J, Gabrielson E, Wang H, Rosner GL, Rusch V, Wolchok JD, Merghoub T, Taube JM, Velculescu VE, Topalian SL, Brahmer JR, Pardoll DM.

N Engl J Med. 2018 May 24;378(21):1976-1986. doi: 10.1056/NEJMoa1716078. Epub 2018 Apr 16.

PMID:
29658848
6.

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.

Hellmann MD, Nathanson T, Rizvi H, Creelan BC, Sanchez-Vega F, Ahuja A, Ni A, Novik JB, Mangarin LMB, Abu-Akeel M, Liu C, Sauter JL, Rekhtman N, Chang E, Callahan MK, Chaft JE, Voss MH, Tenet M, Li XM, Covello K, Renninger A, Vitazka P, Geese WJ, Borghaei H, Rudin CM, Antonia SJ, Swanton C, Hammerbacher J, Merghoub T, McGranahan N, Snyder A, Wolchok JD.

Cancer Cell. 2018 May 14;33(5):843-852.e4. doi: 10.1016/j.ccell.2018.03.018. Epub 2018 Apr 12.

7.

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.

Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC, Chaft JE, Rouche JA, Zitvogel L, Zalcman G, Albiges L, Escudier B, Routy B.

Ann Oncol. 2018 Jun 1;29(6):1437-1444. doi: 10.1093/annonc/mdy103.

PMID:
29617710
8.

Immunotherapy in surgically resectable non-small cell lung cancer.

Owen D, Chaft JE.

J Thorac Dis. 2018 Feb;10(Suppl 3):S404-S411. doi: 10.21037/jtd.2017.12.93. Review.

9.

Adrenal Metastasectomy in the Presence and Absence of Extraadrenal Metastatic Disease.

Russo AE, Untch BR, Kris MG, Chou JF, Capanu M, Coit DG, Chaft JE, D'Angelica MI, Brennan MF, Strong VE.

Ann Surg. 2018 Mar 23. doi: 10.1097/SLA.0000000000002749. [Epub ahead of print]

PMID:
29578911
10.

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N, Hollmann T, Schalper KA, Gainor JF, Shen R, Ni A, Arbour KC, Merghoub T, Wolchok J, Snyder A, Chaft JE, Kris MG, Rudin CM, Socci ND, Berger MF, Taylor BS, Zehir A, Solit DB, Arcila ME, Ladanyi M, Riely GJ, Schultz N, Hellmann MD.

J Clin Oncol. 2018 Mar 1;36(7):633-641. doi: 10.1200/JCO.2017.75.3384. Epub 2018 Jan 16.

PMID:
29337640
11.

Liquid biopsy for ctDNA to revolutionize the care of patients with early stage lung cancers.

Li BT, Stephens D, Chaft JE, Rudin CM, Jones DR, Rusch VW, Rimner A, Isbell JM.

Ann Transl Med. 2017 Dec;5(23):479. doi: 10.21037/atm.2017.09.02.

12.

Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors.

Chaft JE, Hellmann MD, Velez MJ, Travis WD, Rusch VW.

Ann Thorac Surg. 2017 Sep;104(3):e217-e218. doi: 10.1016/j.athoracsur.2017.03.038.

PMID:
28838509
13.

Identifying the Optimal Radiation Dose in Locally Advanced Non-Small-cell Lung Cancer Treated With Definitive Radiotherapy Without Concurrent Chemotherapy.

Sonnick MA, Oro F, Yan B, Desai A, Wu AJ, Shi W, Zhang Z, Gelblum DY, Paik PK, Yorke ED, Rosenzweig KE, Chaft JE, Rimner A.

Clin Lung Cancer. 2018 Jan;19(1):e131-e140. doi: 10.1016/j.cllc.2017.06.019. Epub 2017 Jul 6.

PMID:
28756051
14.

Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas.

Schilsky JB, Ni A, Ahn L, Datta S, Travis WD, Kris MG, Chaft JE, Rekhtman N, Hellmann MD.

Lung Cancer. 2017 Jun;108:205-211. doi: 10.1016/j.lungcan.2017.03.015. Epub 2017 Mar 28.

PMID:
28625636
15.

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

Peters S, Gettinger S, Johnson ML, Jänne PA, Garassino MC, Christoph D, Toh CK, Rizvi NA, Chaft JE, Carcereny Costa E, Patel JD, Chow LQM, Koczywas M, Ho C, Früh M, van den Heuvel M, Rothenstein J, Reck M, Paz-Ares L, Shepherd FA, Kurata T, Li Z, Qiu J, Kowanetz M, Mocci S, Shankar G, Sandler A, Felip E.

J Clin Oncol. 2017 Aug 20;35(24):2781-2789. doi: 10.1200/JCO.2016.71.9476. Epub 2017 Jun 13.

PMID:
28609226
16.

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stages I to IIIA Resectable Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update Summary.

Kris MG, Gaspar LE, Chaft JE, Kennedy EB.

J Oncol Pract. 2017 Jul;13(7):449-451. doi: 10.1200/JOP.2017.022251. Epub 2017 Apr 25. No abstract available.

PMID:
28441082
17.

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update.

Kris MG, Gaspar LE, Chaft JE, Kennedy EB, Azzoli CG, Ellis PM, Lin SH, Pass HI, Seth R, Shepherd FA, Spigel DR, Strawn JR, Ung YC, Weyant M.

J Clin Oncol. 2017 Sep 1;35(25):2960-2974. doi: 10.1200/JCO.2017.72.4401. Epub 2017 Apr 24. Review.

PMID:
28437162
18.

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.

Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, Chang MT, Ni A, Kundra R, Jonsson P, Jayakumaran G, Gao SP, Johnsen HC, Hanrahan AJ, Zehir A, Rekhtman N, Ginsberg MS, Li BT, Yu HA, Paik PK, Drilon A, Hellmann MD, Reales DN, Benayed R, Rusch VW, Kris MG, Chaft JE, Baselga J, Taylor BS, Schultz N, Rudin CM, Hyman DM, Berger MF, Solit DB, Ladanyi M, Riely GJ.

Cancer Discov. 2017 Jun;7(6):596-609. doi: 10.1158/2159-8290.CD-16-1337. Epub 2017 Mar 23.

19.

Definitive Radiotherapy for Local Recurrence of NSCLC After Surgery.

Wu AJ, Garay E, Foster A, Hsu M, Zhang Z, Chaft JE, Huang J, Rosenzweig KE, Rimner A.

Clin Lung Cancer. 2017 May;18(3):e161-e168. doi: 10.1016/j.cllc.2017.01.014. Epub 2017 Feb 21.

20.

The Use of Antiangiogenic Agents for Lung Cancer in Elderly Patients: An Expert Panel Discussion Synopsis.

Socinski MA, Chaft JE, Levy B, Riely GJ, Langer CJ, Perez-Soler R, Middleton DL, Gracie-King L, Healy LM.

Clin Lung Cancer. 2017 May;18(3):255-258. doi: 10.1016/j.cllc.2016.12.001. Epub 2017 Jan 5. No abstract available.

PMID:
28188100
21.

Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer.

Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, Rodriguez C, Cambridge L, Rizvi H, Wolchok JD, Merghoub T, Rudin CM, Fish S, Hellmann MD.

Ann Oncol. 2017 Mar 1;28(3):583-589. doi: 10.1093/annonc/mdw640.

22.

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, Rosenberg J, Voss MH, Rudin CM, Rizvi H, Hou X, Rodriguez K, Albano M, Gordon RA, Leduc C, Rekhtman N, Harris B, Menzies AM, Guminski AD, Carlino MS, Kong BY, Wolchok JD, Postow MA, Long GV, Hellmann MD.

J Clin Oncol. 2017 Mar;35(7):709-717. doi: 10.1200/JCO.2016.68.2005. Epub 2016 Sep 30.

23.

Have adjuvant tyrosine kinase inhibitors lost their shine?

Sabari JK, Chaft JE.

Ann Transl Med. 2016 Aug;4(15):285. doi: 10.21037/atm.2016.07.18.

24.

Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.

Eng J, Hsu M, Chaft JE, Kris MG, Arcila ME, Li BT.

Lung Cancer. 2016 Sep;99:53-6. doi: 10.1016/j.lungcan.2016.05.030. Epub 2016 May 31.

25.

Chemotherapy remains an essential element of personalized care for persons with lung cancers.

Hellmann MD, Li BT, Chaft JE, Kris MG.

Ann Oncol. 2016 Oct;27(10):1829-35. doi: 10.1093/annonc/mdw271. Epub 2016 Jul 25. Review.

26.

Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.

Naidoo J, Schindler K, Querfeld C, Busam K, Cunningham J, Page DB, Postow MA, Weinstein A, Lucas AS, Ciccolini KT, Quigley EA, Lesokhin AM, Paik PK, Chaft JE, Segal NH, D'Angelo SP, Dickson MA, Wolchok JD, Lacouture ME.

Cancer Immunol Res. 2016 May;4(5):383-9. doi: 10.1158/2326-6066.CIR-15-0123. Epub 2016 Feb 29.

27.

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.

Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, Narwal R, Steele K, Gu Y, Karakunnel JJ, Rizvi NA.

Lancet Oncol. 2016 Mar;17(3):299-308. doi: 10.1016/S1470-2045(15)00544-6. Epub 2016 Feb 6.

28.

Adaptive Neoadjuvant Chemotherapy Guided by (18)F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial.

Chaft JE, Dunphy M, Naidoo J, Travis WD, Hellmann M, Woo K, Downey R, Rusch V, Ginsberg MS, Azzoli CG, Kris MG.

J Thorac Oncol. 2016 Apr;11(4):537-44. doi: 10.1016/j.jtho.2015.12.104. Epub 2015 Dec 25.

29.

HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers.

Li BT, Ross DS, Aisner DL, Chaft JE, Hsu M, Kako SL, Kris MG, Varella-Garcia M, Arcila ME.

J Thorac Oncol. 2016 Mar;11(3):414-9. doi: 10.1016/j.jtho.2015.10.025. Epub 2015 Dec 24.

30.

HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib.

Li BT, Lee A, O'Toole S, Cooper W, Yu B, Chaft JE, Arcila ME, Kris MG, Pavlakis N.

Lung Cancer. 2015 Dec;90(3):617-9. doi: 10.1016/j.lungcan.2015.10.025. Epub 2015 Oct 29.

31.

Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas.

Eng J, Woo KM, Sima CS, Plodkowski A, Hellmann MD, Chaft JE, Kris MG, Arcila ME, Ladanyi M, Drilon A.

J Thorac Oncol. 2015 Dec;10(12):1713-9. doi: 10.1097/JTO.0000000000000671.

32.

Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival.

Ujiie H, Kadota K, Chaft JE, Buitrago D, Sima CS, Lee MC, Huang J, Travis WD, Rizk NP, Rudin CM, Jones DR, Adusumilli PS.

J Clin Oncol. 2015 Sep 10;33(26):2877-84. doi: 10.1200/JCO.2015.60.9818. Epub 2015 Aug 10.

33.

Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation.

Chaft JE, Litvak A, Arcila ME, Patel P, D'Angelo SP, Krug LM, Rusch V, Mattson A, Coeshott C, Park B, Apelian DM, Kris MG, Azzoli CG.

Clin Lung Cancer. 2014 Nov;15(6):405-10. doi: 10.1016/j.cllc.2014.06.002. Epub 2014 Jun 21.

PMID:
25044103
34.

Chemotherapy for lung cancers: here to stay.

Kris MG, Hellmann MD, Chaft JE.

Am Soc Clin Oncol Educ Book. 2014:e375-80. doi: 10.14694/EdBook_AM.2014.34.e375. Review.

35.

Serpins promote cancer cell survival and vascular co-option in brain metastasis.

Valiente M, Obenauf AC, Jin X, Chen Q, Zhang XH, Lee DJ, Chaft JE, Kris MG, Huse JT, Brogi E, Massagué J.

Cell. 2014 Feb 27;156(5):1002-16. doi: 10.1016/j.cell.2014.01.040.

36.

Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint.

Hellmann MD, Chaft JE, William WN Jr, Rusch V, Pisters KM, Kalhor N, Pataer A, Travis WD, Swisher SG, Kris MG; University of Texas MD Anderson Lung Cancer Collaborative Group.

Lancet Oncol. 2014 Jan;15(1):e42-50. doi: 10.1016/S1470-2045(13)70334-6. Review.

37.

Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.

Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, Lathan CS, Moran T, Sequist LV, Chaft JE, Riely GJ, Arcila ME, Soo RA, Meyerson M, Eck MJ, Kobayashi SS, Costa DB.

Sci Transl Med. 2013 Dec 18;5(216):216ra177. doi: 10.1126/scitranslmed.3007205. Erratum in: Sci Transl Med. 2014 Feb 26;6(225):225er1.

38.

Phase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancers.

Chaft JE, Rekhtman N, Sima CS, Rusch V, Kris MG, Zakowski M, Azzoli CG.

Cancer Chemother Pharmacol. 2013 Oct;72(4):931-4. doi: 10.1007/s00280-013-2263-1. Epub 2013 Aug 22.

39.

Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers.

Chaft JE, Rusch V, Ginsberg MS, Paik PK, Finley DJ, Kris MG, Price KA, Azzoli CG, Fury MG, Riely GJ, Krug LM, Downey RJ, Bains MS, Sima CS, Rizk N, Travis WD, Rizvi NA.

J Thorac Oncol. 2013 Aug;8(8):1084-90. doi: 10.1097/JTO.0b013e31829923ec.

40.

Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab.

Hellmann MD, Chaft JE, Rusch V, Ginsberg MS, Finley DJ, Kris MG, Price KA, Azzoli CG, Fury MG, Riely GJ, Krug LM, Downey RJ, Bains MS, Sima CS, Rizk N, Travis WD, Rizvi NA, Paik PK.

Cancer Chemother Pharmacol. 2013 Aug;72(2):453-61. doi: 10.1007/s00280-013-2219-5. Epub 2013 Jun 28.

41.

EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.

Arcila ME, Nafa K, Chaft JE, Rekhtman N, Lau C, Reva BA, Zakowski MF, Kris MG, Ladanyi M.

Mol Cancer Ther. 2013 Feb;12(2):220-9. doi: 10.1158/1535-7163.MCT-12-0620. Epub 2013 Jan 31.

42.

Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers.

Varghese AM, Sima CS, Chaft JE, Johnson ML, Riely GJ, Ladanyi M, Kris MG.

J Thorac Oncol. 2013 Jan;8(1):123-5. doi: 10.1097/JTO.0b013e31827914ea.

43.

Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma.

Rekhtman N, Tafe LJ, Chaft JE, Wang L, Arcila ME, Colanta A, Moreira AL, Zakowski MF, Travis WD, Sima CS, Kris MG, Ladanyi M.

Mod Pathol. 2013 Apr;26(4):511-22. doi: 10.1038/modpathol.2012.195. Epub 2012 Nov 30. Erratum in: Mod Pathol. 2014 Jan;27(1):163.

44.

Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.

D'Angelo SP, Janjigian YY, Ahye N, Riely GJ, Chaft JE, Sima CS, Shen R, Zheng J, Dycoco J, Kris MG, Zakowski MF, Ladanyi M, Rusch V, Azzoli CG.

J Thorac Oncol. 2012 Dec;7(12):1815-1822. doi: 10.1097/JTO.0b013e31826bb7b2.

45.

Clinical outcomes with perioperative chemotherapy in sarcomatoid carcinomas of the lung.

Chaft JE, Sima CS, Ginsberg MS, Huang J, Kris MG, Travis WD, Azzoli CG.

J Thorac Oncol. 2012 Sep;7(9):1400-5. doi: 10.1097/JTO.0b013e3182614856.

46.

Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.

Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M, Paik PK, Zakowski MF, Kris MG, Ladanyi M.

Clin Cancer Res. 2012 Sep 15;18(18):4910-8. doi: 10.1158/1078-0432.CCR-12-0912. Epub 2012 Jul 3.

47.

The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement.

Martins RG, D'Amico TA, Loo BW Jr, Pinder-Schenck M, Borghaei H, Chaft JE, Ganti AK, Kong FM, Kris MG, Lennes IT, Wood DE.

J Natl Compr Canc Netw. 2012 May;10(5):599-613. Review.

PMID:
22570291
48.

ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma.

Chaft JE, Rekhtman N, Ladanyi M, Riely GJ.

J Thorac Oncol. 2012 Apr;7(4):768-9. doi: 10.1097/JTO.0b013e31824c9485. No abstract available.

49.

Incorporation of crizotinib into the NCCN guidelines.

Riely GJ, Chaft JE, Ladanyi M, Kris MG.

J Natl Compr Canc Netw. 2011 Dec;9(12):1328-30. No abstract available.

PMID:
22157552
50.

Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.

Chaft JE, Arcila ME, Paik PK, Lau C, Riely GJ, Pietanza MC, Zakowski MF, Rusch V, Sima CS, Ladanyi M, Kris MG.

Mol Cancer Ther. 2012 Feb;11(2):485-91. doi: 10.1158/1535-7163.MCT-11-0692. Epub 2011 Dec 1.

Supplemental Content

Loading ...
Support Center